PATH-51. OUTCOME IN 1p/19q NON-CO-DELETED GLIOMA TREATED AT FIRST RECURRENCE WITH TEMOZOLOMIDE W/WO BEVACIZUMAB IS DEPENDENT ON IDH MGMT AND CIMP STATUS BUT NOT ON GRADE AT FIRST DIAGNOSIS. A REPORT FROM THE RANDOMIZED PHASE II EORTC TAVAREC TRIAL

摘要

INTRODUCTIONThe TAVAREC randomized controlled phase II trial examined the efficacy of bevacizumab in addition to temozolomide in non-1p19q co-deleted grade II/IIII glioma treated at first recurrence showing contrast enhancement. The trial failed to demonstrate improvement of PFS or OS when bevacizumab was added to temozolomide. Here we present data on the molecular analysis of trial samples.